DEFM14A: Avid Bioservices to be Acquired by GHO Capital and Ampersand Capital Partners for $12.50 Per Share

Avid Bioservices is set to be acquired by funds managed by affiliates of GHO Capital Partners LLP and Ampersand Capital Partners for $12.50 per share in cash.

Summary

• Avid Bioservices, Inc. is being acquired by Space Finco, Inc., owned by funds managed by affiliates of GHO Capital Partners LLP and Ampersand Capital Partners.
• The acquisition will be executed through a merger, with Space Mergerco, Inc. merging into Avid, and Avid continuing as the surviving entity and a wholly owned subsidiary of Parent.
• Avid stockholders will receive $12.50 in cash per share, representing a premium over the stock's closing price on November 6, 2024, and volume-weighted average prices for various periods.
• The Board of Directors of Avid has unanimously approved the merger agreement and recommends that stockholders vote in favor of the proposal.
• A special meeting of Avid stockholders will be held on January 30, 2025, to vote on the merger agreement proposal, an advisory compensation proposal, and a proposal to adjourn the meeting if necessary.
• The transaction is expected to close in the first quarter of 2025, subject to stockholder approval and regulatory approvals.
• Parent has secured debt and equity financing commitments to fund the acquisition, with the equity commitment totaling up to $1,120,000,000.
• Stockholders have the right to seek appraisal of their shares if they meet certain conditions and do not vote in favor of the merger.

Sentiment

Score: 7

Explanation: The document is generally positive, outlining a definitive agreement for acquisition with a premium for stockholders. While risks are mentioned, the overall tone suggests a favorable outcome for Avid Bioservices and its investors.

Positives

• Stockholders will receive a cash payment of $12.50 per share, providing immediate liquidity.
• The acquisition price represents a significant premium over recent trading prices.
• The Board of Directors has unanimously approved the merger, indicating confidence in the deal.
• Committed equity financing ensures the deal is not subject to financing risks.
• Stockholders have appraisal rights if they disagree with the merger terms.

Negatives

• Stockholders will lose any potential future upside from Avid's continued operation as an independent company.
• The merger is subject to customary closing conditions, including regulatory approvals, which could delay or prevent the transaction.
• The agreement includes a termination fee payable by Avid under certain circumstances.
• The transaction will be taxable to Avid stockholders for U.S. federal income tax purposes.

Risks

• The merger may not be completed if the required stockholder approval is not obtained.
• Regulatory approvals may not be received, or may be delayed, potentially preventing the transaction.
• A Material Adverse Effect on Avid could prevent the transaction from closing.
• Litigation could arise challenging the transaction, potentially delaying or preventing its completion.
• The loss of key personnel or disruption of customer relationships could negatively impact Avid's business.

Future Outlook

The merger is expected to close in the first quarter of 2025, subject to customary closing conditions, including stockholder and regulatory approvals.

Management Comments

• The Companys Board of Directors has unanimously determined that the Merger Agreement and the consummation of the transactions contemplated by the Merger Agreement are advisable, and in the best interest of, Avid and its stockholders.
• The Board of Directors unanimously recommends, on behalf of Avid, that you vote FOR the Merger Agreement Proposal; FOR the Compensation Proposal; and FOR the Adjournment Proposal.

Industry Context

The announcement reflects ongoing consolidation activity within the CDMO sector, driven by private equity firms seeking to capitalize on the growing demand for outsourced biopharmaceutical manufacturing services.

Comparison to Industry Standards

• The $12.50 per share consideration represents a premium of approximately 13.8% to the closing price of Avids common stock of $10.98 on November 6, 2024, the last full trading day prior to the announcement of the transaction.
• The $12.50 per share consideration represents a premium of approximately 21.9% to the volume-weighted average price of Avids common stock for the twenty (20) day period ending on the Unaffected Date.
• The $12.50 per share consideration represents a premium of approximately 50.1% to the volume-weighted average price of Avids common stock for the six (6) month period ending on the Unaffected Date.

Stakeholder Impact

• Shareholders will receive $12.50 per share in cash.
• Executive officers may receive certain compensation and benefits in connection with the merger.
• Employees will be provided with comparable compensation and benefits for at least one year following the merger.
• Customers and suppliers may experience changes as a result of the merger.

Next Steps

• Avid will hold a special meeting of stockholders on January 30, 2025, to vote on the merger agreement proposal.
• Avid and Parent will seek to obtain necessary regulatory approvals.
• Avid and Parent will work to satisfy all closing conditions to complete the merger in the first quarter of 2025.

Key Dates

Keywords

merger agreement, acquisition, avid bioservices, gho capital, ampersand capital, stockholders, merger, cdmo, financing, tender offer